Immediate Impact
51 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Oxidative cell death in cancer: mechanisms and therapeutic opportunities
2024 Standout
Works of Д. В. Комов being referenced
Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Д. В. Комов | 153 | 34 | 79 | 105 | 21 | 240 | |
| Rebecca Herbertson | 149 | 21 | 108 | 25 | 18 | 286 | |
| Diego Enrico | 125 | 16 | 28 | 42 | 28 | 195 | |
| Margherita Ambrosini | 224 | 46 | 21 | 48 | 24 | 273 | |
| Nagi S. El-Saghir | 116 | 77 | 14 | 28 | 20 | 264 | |
| Z. Tomasevic | 149 | 39 | 84 | 69 | 24 | 293 | |
| Zhongmin Maxwell Wang | 191 | 14 | 53 | 106 | 17 | 287 | |
| Elske C. Gootjes | 136 | 37 | 102 | 22 | 28 | 275 | |
| Khalid Jazieh | 166 | 27 | 33 | 44 | 24 | 263 | |
| Tobias Lekberg | 146 | 137 | 47 | 27 | 12 | 263 | |
| Lucía López‐Anglada | 62 | 9 | 20 | 29 | 14 | 237 |
All Works
Loading papers...